Thyroid Disease News and Research

RSS

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

12 Aug 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

UT Southwestern dermatologist improves technique to treat skin discoloration from vitiligo

A UT Southwestern Medical Center dermatologist has improved a technique to transplant pigment cells that can repair the affected area of skin discoloration from vitiligo.

17 Jul 2015

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

In a new study of more than 125,000 pregnant women in Sweden, researchers found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

9 Jul 2015

Low and high maternal thyroid hormone levels during pregnancy may affect infant's IQ

A new study finds that not only low but also high maternal thyroid hormone levels during early pregnancy may significantly lower the infant's IQ later in childhood. The study results, which will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego, suggest that the common practice of treating pregnant women who have mild thyroid hormone deficiency may pose unexpected risks to the developing baby's brain.

9 Mar 2015

Trained scent dog identifies thyroid cancer in patients’ urine samples

A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Majority of asymptomatic, benign thyroid nodules remain benign during follow-up

After five years of follow-up, a majority of asymptomatic, benign thyroid nodules exhibited no significant change in size, or actually decreased in size, and diagnoses of thyroid cancer were rare, according to a study in the March 3 issue of JAMA.

4 Mar 2015

Study finds link between fluoridated water and ADHD prevalence

"Artificial water fluoridation prevalence was significantly positively associated with ADHD prevalence," according to research published in Environmental Health (2/15), reports the Fluoride Action Network (FAN).

3 Mar 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Thyroid disease can affect woman's reproductive health

Thyroid disease can have significant effects on a woman's reproductive health and screening for women presenting with fertility problems and recurrent early pregnancy loss should be considered, suggests a new review published today (23 January) in The Obstetrician & Gynaecologist.

23 Jan 2015

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Medical illness common in bipolar disorder

Patients with bipolar disorder have high rates of medical illness, which often exceeds the levels observed in patients with unipolar depression, show results of a UK-based study.

5 Nov 2014

STTM releases most groundbreaking thyroid disease treatment book

Stop the Thyroid Madness LLC and author/editor Janie A. Bowthorpe, M.Ed, announce the release of the most groundbreaking thyroid disease treatment book on the market, totally written by several esteemed medical professionals.

22 Aug 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Eye movement disorder increases as we age, study finds

Abnormal binocular vision, which involves the way eyes work together as a team, increases dramatically as we age, according to research from the University of Waterloo. The study also found a correlation between this condition, general health and antidepressant use.

2 May 2014

Free educational event for patients with Graves' disease and thyroid eye disease

The Massachusetts Eye and Ear and the Graves' Disease & Thyroid Foundation will host a free educational event for patients living with Graves' disease and thyroid eye disease on Saturday, May 10 from 8:30 a.m. to noon at Mass. Eye and Ear's Meltzer Auditorium, 3rd floor, 243 Charles Street, Boston, Mass., 02114.

30 Apr 2014

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013